Ethyl eicosapentaenoic acid/rosuvastatin

Drug Profile

Ethyl eicosapentaenoic acid/rosuvastatin

Alternative Names: AMR-102; Ethyl eicosapentaenoic acid/rosuvastatin - Amarin; Icosapent ethyl/rosuvastatin - Amarin; Vascepa/rosuvastatin - Amarin

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amarin Corporation
  • Class Antihyperlipidaemics; Eicosanoids; Fluorobenzenes; Omega 3 fatty acids; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia in USA (PO)
  • 21 Jun 2013 Safety and pharmacokinetics data from a phase I trial in healthy volunteers released by Amarin
  • 17 Dec 2012 Phase-I clinical trials in Hyperlipidaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top